Non-Viral And Large-Scale Delivery Of Gene Editing Tools For T-Cell Manufacturing

By Hannah Goldfarb Wittkopf, Frank Morrissey-Wettey, Nadessa Poeppel, Meike Zander, Nicole Kukli, Katharina Stolle, Gina Andretta-Beu, Stefanie Müthel, Valeria Annibaldi, Andrea Toell

Non-viral methods for cell engineering, particularly electroporation, are gaining traction as alternatives to viral transduction and are increasingly present in clinical trials. Historically, challenges included poor scalability and complex optimization, often leading to unsatisfactory large-scale transfection efficiency.

A new generation of electroporation technology, the 4D-Nucleofector LV Unit PRO, directly addresses these limitations. This platform reliably supports non-viral manufacturing of genetically modified T cells. Its features, including an optimized cartridge design and easy scale-up capabilities, enable the robust and efficient delivery of complex, clinically relevant cargos like CRISPR/Cas9 or Transposon/Transposase. The system facilitates the cell engineering process for up to 1 billion cells with minimal optimization efforts required for scaling up and translation to clinical settings.

Discover how this advanced unit provides a reliable, robust, and efficient solution for large-scale gene editing in T-cell manufacturing.